Breelyn Wilky

Breelyn Wilky: Promising outcomes for immune cold sarcomas with BOT/BAL

Breelyn Wilky, Director of Sarcoma Medical Oncology at University of Colorado Anschutz Medical Campus, shared an article she and her colleagues authored on X:

“Very excited to see this in print! Such promising outcomes for immune cold sarcomas with Botensilimab Plus Balstilimab.”

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas

Authors: Breelyn A. Wilky et al.

Breelyn Wilky: Promising outcomes for immune cold sarcomas with BOT/BAL

Andrea J. Bullock Anthony B. El-Khoueiry Apostolia M Tsimberidou Arun Singh Benny Johnson BOT/BAL Breelyn A. Wilky Brian Henick cancer Chloe Delepine Daruka Mahadevan Dhan Chand Gary K. Schwartz Jonathan C. Trent Joseph E. Grossman Justin Stebbing Manushak Avagyan Mark Agulnik Michael S. Gordon OncoDaily Oncology Robin L. Jones Steven O'Day Wei Wu